Renal Cell Carcinoma Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese health-care system perspective.PMID:38506058 | DOI:10.1080/14737167.2024.2333334 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 20, 2024 Category: Health Management Authors: Shuo Kang Jintuo Yin Source Type: research

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese healthcare system perspective.PMID:38506058 | DOI:10.1080/14737167.2024.2333334 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 20, 2024 Category: Health Management Authors: Shuo Kang Jintuo Yin Source Type: research

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
CONCLUSIONS: RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.PMID:38504270 | DOI:10.1186/s13046-024-02984-2 (Source: Cell Research)
Source: Cell Research - March 20, 2024 Category: Cytology Authors: Christopher Montemagno Arnaud Jacquel Charlotte Pandiani Olivia Rastoin Rosie Dawaliby Thomas Schmitt Maxence Bourgoin H éliciane Palenzuela Anne-Laure Rossi Damien Ambrosetti Jerome Durivault Frederic Luciano Delphine Borchiellini Julie Le Du Leticia Ch Source Type: research

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese healthcare system perspective.PMID:38506058 | DOI:10.1080/14737167.2024.2333334 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 20, 2024 Category: Health Management Authors: Shuo Kang Jintuo Yin Source Type: research

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese health-care system perspective.PMID:38506058 | DOI:10.1080/14737167.2024.2333334 (Source: Cell Research)
Source: Cell Research - March 20, 2024 Category: Cytology Authors: Shuo Kang Jintuo Yin Source Type: research

Tumour-to-tumour metastasis of breast cancer (donor) and clear cell renal cell carcinoma (recipient): a case report
A woman in her late 70s was referred to urology clinic to consider intervention for a biopsy-proven 24 mm WHO/International Society of Urological Pathology (ISUP) grade 1 clear cell renal cell carcinoma (CCRCC) that was diagnosed 4 years prior and managed with active surveillance up to that point. The patient had a history of right invasive breast cancer (ductal carcinoma) first diagnosed more than 20 years ago and treated with wide local excision and adjuvant radiotherapy. She developed breast cancer recurrence in the scalp and chest wall 3 years before and was treated with letrozole, with satisfactory disease control. Fo...
Source: Journal of Clinical Pathology - March 20, 2024 Category: Pathology Authors: Hau, J., Briosa Neves, J., Varia, M. Tags: PostScript Source Type: research

Impact of cellular morphology and three-tiered nuclear grade on progression of conventional renal cell carcinoma
Conclusions The three-tiered grading predicts the progression of cRCC irrespectively of cytomorphology. However, the cytomorphology and necrosis show a good correlation with three-tiered grading in estimate disease progression. (Source: Journal of Clinical Pathology)
Source: Journal of Clinical Pathology - March 20, 2024 Category: Pathology Authors: Domonkos, L., Yusenko, M., Kovacs, G., Peterfi, L. Tags: Short report Source Type: research

Chlorogenic acid alleviates acute kidney injury in septic mice by inhibiting NLRP3 inflammasomes and the caspase-1 canonical pyroptosis pathway
CONCLUSION: CGA alleviates AKI in mice with CLP-induced sepsis by inhibiting NLRP3 inflammasomes and the caspase-1 signaling pathway.PMID:38501417 | PMC:PMC10954528 | DOI:10.12122/j.issn.1673-4254.2024.02.14 (Source: Journal of Southern Medical University)
Source: Journal of Southern Medical University - March 19, 2024 Category: Universities & Medical Training Authors: S Fang R Sun H Su K Zhai Y Xiang Y Gao W Guo Source Type: research

Chlorogenic acid alleviates acute kidney injury in septic mice by inhibiting NLRP3 inflammasomes and the caspase-1 canonical pyroptosis pathway
CONCLUSION: CGA alleviates AKI in mice with CLP-induced sepsis by inhibiting NLRP3 inflammasomes and the caspase-1 signaling pathway.PMID:38501417 | DOI:10.12122/j.issn.1673-4254.2024.02.14 (Source: Journal of Southern Medical University)
Source: Journal of Southern Medical University - March 19, 2024 Category: Universities & Medical Training Authors: S Fang R Sun H Su K Zhai Y Xiang Y Gao W Guo Source Type: research